anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: SUVECALTAMIDE
Trial phase: Phase 2
SMILES: CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 86
Group description: MK-8998, 6 mg twice a day (BID) on Days 1 to 7, and 8 mg BID thereafter for a 4-week total treatment period
Eligibility criteria:
Inclusion Criteria:

Patient's age is 18 to 55
Patient meets DSM-IV/DSM-IV-TR criteria for a primary diagnosis of schizophrenia
The duration of the patients schizophrenia diagnosis must be greater than 1 year
Patient has an acute exacerbation of psychotic symptoms (of at least 3 days but no longer than 6 weeks) and marked deterioration of function

Exclusion Criteria:

Patient currently has a clinically significant neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological disorder that would pose a risk to the patient in the opinion of the investigator if they were to participate in the study or that might confound the results of the study
The patient has evidence of acute hepatitis, clinically significant chronic hepatitis, or impaired hepatic function
The patient has a chronic organic disease of the central nervous system (other than schizophrenia) such as, tumors, inflammation, active seizure disorder, vascular disorder, Parkinson's disease, Alzheimer's disease or other forms of dementia, myasthenia gravis, or other degenerative processes. In addition, patients must not have a history of mental retardation or persistent neurological symptoms attributable to serious head injury
Patient has a history of alcohol/drug dependence within 3 months or alcohol/drug abuse within 1 month of screening. Exceptions include caffeine and nicotine abuse/dependence
Patient has a history of hypersensitivity to olanzapine OR poor response to olanzapine in the last 2 years OR intolerable side effects due to olanzapine OR patients current psychotic relapse occurred while consistently taking a therapeutic dose (10 mg or more) of olanzapine OR olanzapine is medically contradicted
Patient is refractory to antipsychotic treatment
Intervention: Progesterone
Trial phase: Phase 3
ATC code: G03DA04 | G03FA04
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](C(C)=O)CC[C@@]21[H]
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 400
Group description: Progesterone vaginal tables 100 mg given twice à day.
Eligibility criteria:
Inclusion Criteria:

Patient has given written informed consent;
BMI < 30 kg/m2;
Age 18 - 42 (upon starting COH);
<3 prior ART cycles (IVF, ICSI and related procedures);
Baseline (day 2-3 of cycling) FSH <15 IU/L and E2 <80 pg/mL;
Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or hysteroscopic exam (i.e. no polyps or protruding submucosal fibroids);
Patients must have at least three retrieved oocytes.

Exclusion Criteria:

Intramural uterine fibroids that distort the uterine cavity or polyps >1 cm;
Stage III or IV endometriosis (no endometriomas);
Hydrosalpinges;
History of past poor response to COH resulting in canceling ART;
Use of thawed/donated oocytes;
Use of thawed/donated embryos;
Gestational carrier;
Patients affected by pathologies associated with any contraindication of being pregnant;
Hypersensitivity to study medication;
Uncontrolled adrenal or thyroid dysfunction;
History of conditions (i.e. toxic shock syndrome) that would contraindicate use of a vaginal progesterone product;
History of arterial disease;
Patients with hepatic impairment (liver function tests > 2x upper limits of normal);
Patients with dermatologic disease;
Patients with renal impairment (estimated creatinine clearance <60 mL/min/1.73 m2);
Neoplasias (current) or history of neoplasia that may be responsive to progesterone;
High grade cervical dysplasia;
History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages, wherein pregnancy developed to a minimum of a gestational sac on TVUS;
Participation in a concurrent clinical trial or in another trial within the past 2 months;
Use of concomitant medications that might interfere with the study evaluation;
Pre-implantation genetic diagnosis/screening
Intervention: Ixabepilone
Trial phase: Phase 2
ATC code: L01DC04
SMILES: [H][C@]12C[C@@H](/C(C)=C/c3csc(C)n3)NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy will occur 2-8 weeks after completion of chemotherapy.
Eligibility criteria:
Inclusion Criteria:

Histologic documentation of prostatic adenocarcinoma. Patients with small cell, neuroendocrine or transitional cell carcinomas are not eligible.
All eligible patients must have a known Gleason sum based on biopsy or TURP at the time of registration.
Clinically Localized Disease: Patients must have clinical stage T1-T3a and no radiographic evidence of metastatic disease as demonstrated by:
Either CT or MRI of the abdomen and pelvis, that demonstrate no nodes > 1 cm: or endorectal MRI(If one or more lymph nodes(s) measures > 1 cm, a negative biopsy is required.)
Negative bone scan (with plain films and /or MRI and/or CT scan confirmation, if necessary).(Positive PET and Prostascint scans are not considered proof of metastatic disease.)

Patients must have high risk disease defined as either:

Gleason Score 8-10
PSA > 15 ng/ml
Stage T3a
Stage T2c and Gleason score of 7
Stage T2b, Gleason score of 7, greater than 50% of the cores positive from a single lobe.
No prior treatment for prostate cancer including prior surgery (excluding TURP), pelvic lymph node dissection, radiation therapy, chemotherapy or hormone therapy.
Patient must be appropriate candidates for radical prostatectomy with an estimated life expectancy > 10 years as determined by an urologist.
ECOG PS 0-1
Age > 18 years of age.

Required initial laboratory values:

ANC > 1500/ul
Platelet count > 100,000/mm3
Creatinine < 2.0 mg/dl
Serum PSA < 100 ng/ml
Bilirubin < upper institutional limit of normal (ULN)
AST/ALT < 2.5 X ULN

Exclusion Criteria:

Active or uncontrolled infection.
Patients must not have other coexistent medical condition that would preclude protocol therapy.
Previous severe hypersensitivity reaction to a drug formulated in CremophoreL (polyoxyethylated castor oil).
Grade 1 or greater neuropathy (motor or sensory) at study entry
Intervention: Desonide
Trial phase: Phase 4
ATC code: D07AB08 | D07BB02 | S01BA11
SMILES: [H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 50
Group description: Desonide Cream 0.05%
Eligibility criteria:
Inclusion Criteria:

at least 3 months of age and less than 13 years of age
atopic dermatitis of moderate severity

Exclusion Criteria:

pregnant or lactating
treatment of atopic dermatitis with topical product in the 14 days prior to Baseline
treatment of atopic dermatitis with systemic product in the 30 days prior to Baseline
serious or uncontrolled medical condition
active infection
significant use of inhaled, intranasal, or intraocular corticosteroid
Intervention: Etonogestrel
Trial phase: Not Applicable
ATC code: G03AC08
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@@]21[H]
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Twenty women were allocated to receive the ETGreleasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery
Eligibility criteria:
Inclusion Criteria:

age between 18 and 35 years
Postpartum contraception desire

Exclusion Criteria:

smoking, alcoholism or drug addiction
presence of systemic diseases (diabetis melittus, cardiovascular disease, autoimmune diseases, liver disease, thyroid disease, or congenital renal hyperplasia)
having a body mass index ≥ 30 kg/m2
personal history of arterial or venous thrombosis
using any medication that might interfere with blood coagulation or with the assessment of haemostatic and inflammatory variables
presenting alterations in hepatic enzymes
being allergic to local anaesthetics (xylocaine)
Intervention: Nebivolol
Trial phase: Phase 2 | Phase 3
ATC code: C07AB12 | C07BB12 | C07FB12 | C09DX05
SMILES: OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 34
Group description: Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached

nebivolol
Eligibility criteria:
Inclusion Criteria:

Established Type 2 diabetic not treated with insulin
Stage 1 hypertensives blood pressure > 130/80 mmHg and < 160/100 mmHg
BMI < 35
Hemoglobin A1C < 8.5
Must be postmenopausal or taking some form of birth control of surgically sterile

Exclusion Criteria:

Acute myocardial infarction, unstable angina, stroke or TIA within the past year.
Active angina in the last three months
Diabetes requiring treatment with insulin
Severe asthma
Female who are pregnant, planning to be pregnant during the study period, lactating or women of childbearing potential who are not using a medically approved method of contraception
Recent history of substance or alcohol abuse .
Uncontrolled hypertension systolic blood pressure >160mmHg or diastolic blood pressure > 100 mmHg
Intervention: Metoprolol
Trial phase: Phase 2 | Phase 3
ATC code: C07AB02 | C07BB02 | C07BB52 | C07CB02 | C07FB02 | C07FB13 | C07FX03 | C07FX05
SMILES: COCCc1ccc(OCC(O)CNC(C)C)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 36
Group description: Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached

Metoprolol
Eligibility criteria:
Inclusion Criteria:

Established Type 2 diabetic not treated with insulin
Stage 1 hypertensives blood pressure > 130/80 mmHg and < 160/100 mmHg
BMI < 35
Hemoglobin A1C < 8.5
Must be postmenopausal or taking some form of birth control of surgically sterile

Exclusion Criteria:

Acute myocardial infarction, unstable angina, stroke or TIA within the past year.
Active angina in the last three months
Diabetes requiring treatment with insulin
Severe asthma
Female who are pregnant, planning to be pregnant during the study period, lactating or women of childbearing potential who are not using a medically approved method of contraception
Recent history of substance or alcohol abuse .
Uncontrolled hypertension systolic blood pressure >160mmHg or diastolic blood pressure > 100 mmHg
Intervention: Propranolol
Trial phase: Phase 2
ATC code: C07AA05 | C07BA05 | C07FX01
SMILES: CC(C)NCC(O)COc1cccc2ccccc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Propranolol : 40 mg administered once. The subjects analyzed who received propranolol were those that received the medication and completed both the test and retrieval sessions (Test Day 1 and 2).
Eligibility criteria:
Inclusion Criteria:

Current cocaine dependence (within past month)
Able to provide informed consent
Use of birth control by female participants (barrier methods, surgical sterilization, IUD, or abstinence)
Live within 50-mile radius of research site
Consent to remain abstinent from all drugs of abuse (except nicotine) for 24 hours prior to inpatient admission and follow-up assessment
Consent to random assignment to propranolol or placebo

Exclusion Criteria:

Women who are pregnant, nursing or are of childbearing potential and not practicing/using birth control
Evidence or history of significant hematological, endocrine, cardiovascular, pulmonary, renal, gastrointestinal or neurological disease
Significant liver impairment
History of or current psychotic disorder, current severe major depressive disorder, bipolar affective disorder or a severe anxiety disorder
Currently taking anti-arrhythmic agents, psychostimulants or other agents known to interfere with heart rate and skin conductance monitoring
Known or suspected hypersensitivity to propranolol
Individuals taking medications that could adversely interact with the study medication, including, but not limited to albuterol, insulin, or significant inhibitors of CYP2D6
Individuals with bronchial asthma or chronic obstructive pulmonary disease
Intervention: Memantine
Trial phase: Phase 2
ATC code: N06DA52 | N06DA53 | N06DX01
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: 10-30mg tablets of memantine taken once daily by mouth
Eligibility criteria:
Inclusion Criteria:

men and women age 18-65
current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB)
buying behavior within 2 weeks prior to enrollment

Exclusion Criteria:

infrequent buying (i.e. less than one time per week) that does not meet proposed criteria for CB
unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen
history of seizures
myocardial infarction within 6 months
current pregnancy or lactation, or inadequate contraception in women of childbearing potential
a need for medication other than memantine with possible psychotropic effects or unfavorable interactions;
clinically significant suicidality;
current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence
lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID
current or recent (past 3 months) DSM-IV substance abuse or dependence;
positive urine drug screen at screening
initiation of psychotherapy or behavior therapy within 3 months prior to study baseline
previous treatment with memantine
treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline
Intervention: Progesterone
Trial phase: Not Applicable
ATC code: G03DA04 | G03FA04
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](C(C)=O)CC[C@@]21[H]
Sex: Female
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 144
Group description: The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
Eligibility criteria:
Inclusion Criteria:

Pregnancy 20 - 34 weeks; cervical dilation <4 cm; risk for preterm birth; multifetal gestation; diagnosis of preterm labor during the current pregnancy effectively tocolyzed); preterm rupture of the fetal membranes (24 - 34 weeks); willing and able to sign Informed Consent Form

Exclusion Criteria:

Failure to meet inclusion criteria as noted above; contraindication to pregnancy continuation; severe medical diseases such as sickle cell disease with crises, diabetes mellitus (F/R/H), severe preeclampsia etc., (physician judgment; severe fetal/obstetric criteria such as intrauterine growth restriction (<5th percentile, placental abruption,placental previa, etc., (physician judgment); non reassuring fetal assessment; allergy to progesterone compounds; refusal to participate
Intervention: Prasugrel
Trial phase: Phase 3
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 122
Group description: Primary = participant weight ≥60 kg and age <75 years. Loading dose 30mg followed by maintenance dose 7.5 mg/day
Eligibility criteria:
Inclusion Criteria:

A person who has been diagnosed with acute coronary syndrome (ACS) and is to undergo a percutaneous coronary intervention (PCI)
A person who is of East or Southeast Asian descent
A person who is of the legal age of 18 (or age 21 in Singapore) and is mentally competent to provide a signed written informed consent before entering the study
If a woman is of childbearing potential, she must test negative for pregnancy and agree to use a reliable method of birth control

Exclusion Criteria:

A person who has a severe cardiovascular condition such as cardiogenic shock at the time of randomization, ventricular arrhythmias or congestive heart failure
A person who is at an increased risk of bleeding (e.g. active internal bleeding, history of bleeding disorder, recent fibrinolytic therapy before randomization into the study)
A person who has prior history of any one of the following: ischemic or hemorrhagic stroke; intracranial neoplasm, arteriovenous malformation, or aneurysm; prior history of transient ischemic attack (TIA)
A person who needs to take other antiplatelet therapy other than Aspirin for the duration of the study
A person who receives daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued
A person who has a severe liver disease, such as cirrhosis
A person who has a condition such as alcoholism, mental illness, or drug dependence
Intervention: Prasugrel
Trial phase: Phase 3
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 133
Group description: Primary = participant weight ≥60 kg and age <75 years. Loading dose 30 mg followed by maintenance dose 5 mg/day.
Eligibility criteria:
Inclusion Criteria:

A person who has been diagnosed with acute coronary syndrome (ACS) and is to undergo a percutaneous coronary intervention (PCI)
A person who is of East or Southeast Asian descent
A person who is of the legal age of 18 (or age 21 in Singapore) and is mentally competent to provide a signed written informed consent before entering the study
If a woman is of childbearing potential, she must test negative for pregnancy and agree to use a reliable method of birth control

Exclusion Criteria:

A person who has a severe cardiovascular condition such as cardiogenic shock at the time of randomization, ventricular arrhythmias or congestive heart failure
A person who is at an increased risk of bleeding (e.g. active internal bleeding, history of bleeding disorder, recent fibrinolytic therapy before randomization into the study)
A person who has prior history of any one of the following: ischemic or hemorrhagic stroke; intracranial neoplasm, arteriovenous malformation, or aneurysm; prior history of transient ischemic attack (TIA)
A person who needs to take other antiplatelet therapy other than Aspirin for the duration of the study
A person who receives daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued
A person who has a severe liver disease, such as cirrhosis
A person who has a condition such as alcoholism, mental illness, or drug dependence
Intervention: Prasugrel
Trial phase: Phase 3
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 91
Group description: Low Weight/Elderly = participant weight <60 kg or age ≥75 years. Loading dose 30 mg followed by maintenance dose 5 mg/day.
Eligibility criteria:
Inclusion Criteria:

A person who has been diagnosed with acute coronary syndrome (ACS) and is to undergo a percutaneous coronary intervention (PCI)
A person who is of East or Southeast Asian descent
A person who is of the legal age of 18 (or age 21 in Singapore) and is mentally competent to provide a signed written informed consent before entering the study
If a woman is of childbearing potential, she must test negative for pregnancy and agree to use a reliable method of birth control

Exclusion Criteria:

A person who has a severe cardiovascular condition such as cardiogenic shock at the time of randomization, ventricular arrhythmias or congestive heart failure
A person who is at an increased risk of bleeding (e.g. active internal bleeding, history of bleeding disorder, recent fibrinolytic therapy before randomization into the study)
A person who has prior history of any one of the following: ischemic or hemorrhagic stroke; intracranial neoplasm, arteriovenous malformation, or aneurysm; prior history of transient ischemic attack (TIA)
A person who needs to take other antiplatelet therapy other than Aspirin for the duration of the study
A person who receives daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued
A person who has a severe liver disease, such as cirrhosis
A person who has a condition such as alcoholism, mental illness, or drug dependence
Intervention: Tamsulosin
Trial phase: Not Applicable
ATC code: G01AE10 | G04CA02 | G04CA52 | G04CA53 | G04CA54
SMILES: CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 45
Group description: Patients received one pill of Tamsulosin 400 micrograms once daily
Eligibility criteria:
Inclusion criteria:

patients with a single 2 to 7mm ureteral stone below the common iliac vessels

Exclusion criteria:

presence of multiple ureteral stones
renal insufficiency (glomerular filtration rate below 60 ml/min)
urinary tract infection
a solitary kidney
pregnancy
history of ureteral surgery or previous endoscopic procedure
hypersensitivity to tamsulosin
current alpha-blocker, calcium-antagonist or corticosteroid medication